US fate of Auxilium drug in penis disease expected by early September
This article was originally published in Scrip
Shares of Auxilium Pharmaceuticals got a slight 1.47% bump on 27 December after the company said the US FDA has accepted for review the firm's supplemental biologics license application (sBLA) for Xiaflex (collagenase clostridium histolyticum or CCH) as a treatment for Peyronie's disease, a rare progressive condition in which collagen plaque or scar tissue develops on the shaft of the penis, hardening and reducing flexibility, thus causing pain and forcing the penis to bend or arc during erection, often preventing intercourse.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.